Preparing for Advanced Therapy in Relapsed/Refractory Multiple Myeloma

In this segment, Elizabeth reflects on the period following her stem cell transplant, when she was able to maintain an active lifestyle for a time before her disease progressed again. As her relapsed/refractory multiple myeloma became more active, CAR-T cell therapy emerged as the next treatment approach, with bridging therapy used while preparing for CAR-T treatment. Elizabeth discusses her decision-making process, including conducting her own research, seeking a second opinion, and having detailed conversations with Samantha and other members of her healthcare team about talquetamab. She describes how these discussions helped her understand what to expect, particularly regarding the potential adverse effects associated with treatment. Elizabeth emphasizes the difference between understanding potential toxicities in theory and experiencing them firsthand, noting that preparation can provide important context but may not fully convey the lived experience of treatment. The segment highlights the importance of informed decision-making, realistic expectations, and open communication when preparing for advanced therapy in relapsed/refractory multiple myeloma.